Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Estazolam is a potent benzodiazepine derivative widely recognized in clinical pharmacology for its anxiolytic, sedative, and hypnotic properties. Chemically identified by the CAS number 29680-74-4, this compound features the molecular formula C15H11ClN4O. Its structure consists of a fused triazole ring attached to a chlorinated benzene moiety, which contributes significantly to its metabolic stability and prolonged duration of action compared to other agents in its class.
Primarily prescribed as a short-term treatment for insomnia, Estazolam acts by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at the GABA-A receptor complex within the central nervous system. This mechanism facilitates rapid sleep onset and reduces nighttime awakenings, making it particularly effective for patients suffering from difficulty initiating or maintaining sleep. Unlike some shorter-acting benzodiazepines, Estazolam possesses an intermediate half-life, typically ranging between ten to twenty-four hours, which helps minimize residual daytime drowsiness while ensuring sustained therapeutic coverage throughout the night.
Despite its efficacy, the drug carries significant risks associated with long-term use, including tolerance, physical dependence, and potential withdrawal symptoms upon discontinuation. Consequently, medical guidelines strictly recommend limiting therapy to two to four weeks to mitigate these adverse outcomes. Common side effects may include dizziness, lethargy, headache, and impaired coordination, necessitating caution when operating machinery or driving. Furthermore, concurrent use with alcohol or other central nervous system depressants can lead to severe respiratory depression and heightened toxicity.
While Estazolam remains a valuable tool in managing acute sleep disturbances, its prescription requires careful patient assessment and monitoring. It is contraindicated in individuals with a history of substance abuse, severe respiratory insufficiency, or acute narrow-angle glaucoma. As with all controlled substances, regulatory bodies enforce strict dispensing protocols to prevent misuse. Ongoing research continues to evaluate safer alternatives, yet Estazolam maintains a specific niche in modern sleep medicine where rapid efficacy and intermediate duration are clinically prioritized under professional supervision.